Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 37

1.

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the north central cancer treatment group n9831 adjuvant trastuzumab trial.

Perez EA, Thompson EA, Ballman KV, Anderson SK, Asmann YW, Kalari KR, Eckel-Passow JE, Dueck AC, Tenner KS, Jen J, Fan JB, Geiger XJ, McCullough AE, Chen B, Jenkins RB, Sledge GW, Winer EP, Gralow JR, Reinholz MM.

J Clin Oncol. 2015 Mar 1;33(7):701-8. doi: 10.1200/JCO.2014.57.6298. Epub 2015 Jan 20.

PMID:
25605861
2.

Sinonasal phosphaturic mesenchymal tumor: Case report and systematic review.

Deep NL, Cain RB, McCullough AE, Hoxworth JM, Lal D.

Allergy Rhinol (Providence). 2014 Jan;5(3):162-7. doi: 10.2500/ar.2014.5.0100.

3.

ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer.

Reese JM, Suman VJ, Subramaniam M, Wu X, Negron V, Gingery A, Pitel KS, Shah SS, Cunliffe HE, McCullough AE, Pockaj BA, Couch FJ, Olson JE, Reynolds C, Lingle WL, Spelsberg TC, Goetz MP, Ingle JN, Hawse JR.

BMC Cancer. 2014 Oct 7;14:749. doi: 10.1186/1471-2407-14-749.

4.

EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial.

Cheng H, Ballman K, Vassilakopoulou M, Dueck AC, Reinholz MM, Tenner K, Gralow J, Hudis C, Davidson NE, Fountzilas G, McCullough AE, Chen B, Psyrri A, Rimm DL, Perez EA.

Br J Cancer. 2014 Sep 9;111(6):1065-71. doi: 10.1038/bjc.2014.442. Epub 2014 Aug 12.

PMID:
25117817
5.

Synovial sarcoma presenting as an avascular mass: radiologic-pathologic correlation.

McCullough AE, Schwartz AJ, Taylor VL, Kransdorf MJ.

Skeletal Radiol. 2015 Feb;44(2):279-84. doi: 10.1007/s00256-014-1964-9. Epub 2014 Aug 1.

PMID:
25081635
6.

Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.

Borad MJ, Champion MD, Egan JB, Liang WS, Fonseca R, Bryce AH, McCullough AE, Barrett MT, Hunt K, Patel MD, Young SW, Collins JM, Silva AC, Condjella RM, Block M, McWilliams RR, Lazaridis KN, Klee EW, Bible KC, Harris P, Oliver GR, Bhavsar JD, Nair AA, Middha S, Asmann Y, Kocher JP, Schahl K, Kipp BR, Barr Fritcher EG, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Phillips L, McDonald J, Adkins J, Mastrian SD, Placek P, Watanabe AT, Lobello J, Han H, Von Hoff D, Craig DW, Stewart AK, Carpten JD.

PLoS Genet. 2014 Feb 13;10(2):e1004135. doi: 10.1371/journal.pgen.1004135. eCollection 2014 Feb.

7.

Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.

McCullough AE, Dell'orto P, Reinholz MM, Gelber RD, Dueck AC, Russo L, Jenkins RB, Andrighetto S, Chen B, Jackisch C, Untch M, Perez EA, Piccart-Gebhart MJ, Viale G.

Breast Cancer Res Treat. 2014 Feb;143(3):485-92. doi: 10.1007/s10549-013-2827-0. Epub 2014 Jan 7.

8.

Papillary lesions on core breast biopsy: excisional biopsy for all patients?

McGhan LJ, Pockaj BA, Wasif N, Giurescu ME, McCullough AE, Gray RJ.

Am Surg. 2013 Dec;79(12):1238-42.

PMID:
24351348
9.

Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype.

McGhan LJ, McCullough AE, Protheroe CA, Dueck AC, Lee JJ, Nunez-Nateras R, Castle EP, Gray RJ, Wasif N, Goetz MP, Hawse JR, Henry TJ, Barrett MT, Cunliffe HE, Pockaj BA.

Ann Surg Oncol. 2014 Feb;21(2):361-7. doi: 10.1245/s10434-013-3260-7. Epub 2013 Sep 18.

PMID:
24046116
10.

Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.

Dueck AC, Reinholz MM, Geiger XJ, Tenner K, Ballman K, Jenkins RB, Riehle D, Chen B, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow J, Harris LN, Ingle JN, Lingle WL, Perez EA.

Clin Cancer Res. 2013 Oct 15;19(20):5798-807. doi: 10.1158/1078-0432.CCR-13-0558. Epub 2013 Aug 21.

11.

Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.

Perez EA, Dueck AC, McCullough AE, Chen B, Geiger XJ, Jenkins RB, Lingle WL, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Harris LN, Gralow JR, Reinholz MM.

J Clin Oncol. 2013 Jun 10;31(17):2115-22. doi: 10.1200/JCO.2012.42.2642. Epub 2013 May 6.

12.

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.

Moreno-Aspitia A, Dueck AC, Ghanem-Cañete I, Patel T, Dakhil S, Johnson D, Franco S, Kahanic S, Colon-Otero G, Tenner KS, Rodeheffer R, McCullough AE, Jenkins RB, Palmieri FM, Northfelt D, Perez EA.

Breast Cancer Res Treat. 2013 Apr;138(2):427-35. doi: 10.1007/s10549-013-2469-2. Epub 2013 Mar 12.

13.

Deep clonal profiling of formalin fixed paraffin embedded clinical samples.

Holley T, Lenkiewicz E, Evers L, Tembe W, Ruiz C, Gsponer JR, Rentsch CA, Bubendorf L, Stapleton M, Amorese D, Legendre C, Cunliffe HE, McCullough AE, Pockaj B, Craig D, Carpten J, Von Hoff D, Iacobuzio-Donahue C, Barrett MT.

PLoS One. 2012;7(11):e50586. doi: 10.1371/journal.pone.0050586. Epub 2012 Nov 30.

14.

Atypical ductal hyperplasia on core biopsy: an automatic trigger for excisional biopsy?

McGhan LJ, Pockaj BA, Wasif N, Giurescu ME, McCullough AE, Gray RJ.

Ann Surg Oncol. 2012 Oct;19(10):3264-9. doi: 10.1245/s10434-012-2575-0. Epub 2012 Aug 10.

PMID:
22878619
15.

Histologic remission of cardiac amyloidosis: a case report.

Nelson MR, Lanza LA, Reeder CB, Scott RL, McCullough AE, Chandrasekaran K, Click RL.

Amyloid. 2012 Jun;19(2):106-9. doi: 10.3109/13506129.2012.660892. Epub 2012 Mar 7.

PMID:
22394355
16.

Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.

Perez EA, Dueck AC, McCullough AE, Reinholz MM, Tenner KS, Davidson NE, Gralow J, Harris LN, Kutteh LA, Hillman DW, Jenkins RB, Chen B.

J Natl Cancer Inst. 2012 Jan 18;104(2):159-62. doi: 10.1093/jnci/djr490. Epub 2011 Dec 2.

17.

Influence of uncommon histology on breast conservation therapy for breast cancer-biology dictates technique?

Wasif N, McCullough AE, Gray RJ, Pockaj BA.

J Surg Oncol. 2012 May;105(6):586-90. doi: 10.1002/jso.22132. Epub 2011 Nov 7.

PMID:
22065479
18.

The changing landscape of axillary surgery: which breast cancer patients may still benefit from complete axillary lymph node dissection?

McGhan LJ, Dueck AC, Gray RJ, Wasif N, McCullough AE, Pockaj BA.

J Surg Oncol. 2012 Sep 1;106(3):254-9. doi: 10.1002/jso.22131. Epub 2011 Oct 27.

PMID:
22034211
19.

Primary ovarian malignant lymphoma presenting as ovarian carcinomatosis: a case report and literature review.

Kapetanakis V, Karlin NJ, McCullough AE, Magtibay PM.

Eur J Gynaecol Oncol. 2010;31(6):701-2. Review.

PMID:
21319522
20.

Progression of pelvic implants to complex atypical endometrial hyperplasia after uterine morcellation.

Kill LM, Kapetanakis V, McCullough AE, Magrina JF.

Obstet Gynecol. 2011 Feb;117(2 Pt 2):447-9. doi: 10.1097/AOG.0b013e3181f2e0c6.

PMID:
21252784
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk